Eli Lilly launches clinical trial of COVID-19 antibody treatment
June 2, 2020Manufacturing and Production COVID-19, coronavirus
Eli Lilly has announced they have started an early stage human trial to test an antibody treatment against coronavirus. The …
Sanofi’s Sarclisa combo approved in Europe for relapsed/refractory multiple myeloma
June 2, 2020Manufacturing and Production, Sales and Marketing Europe, Sanofi, Sarclisa, pharma
Sanofi has scored a new approval from the European Commission for the use of its CD38 inhibitor Sarclisa (isatuximab) in …
AI firm that worked with Vote Leave awarded contract to help Britain deal with COVID-19
June 2, 2020Manufacturing and Production
The AI company Faculty, who worked on the Vote Leave campaign, have been awarded a £400,000 contract by the government …
Antidepressant Zoloft falls into shortage due to anxiety around COVID-19
June 2, 2020Manufacturing and Production COVID-19, coronavirus
The FDA has listed the antidepressant Zoloft to its catalogue of drugs that are in short supply in the United …
Five-day remdesivir regimen shows promising clinical benefit in COVID-19 patients, Phase 3 data shows
June 2, 2020Manufacturing and Production, Research and Development COVID-19, Gilead, coronavirus, pharma, remdesivir
Gilead has unveiled eagerly anticipated new Phase 3 data on the addition of its antiviral therapy remdesivir to standard of …
Ipsen appoints David Loew as new Chief Executive Officer
June 1, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
David Loew will leave his position as the head of Sanofi’s vaccine division to become the Chief Executive Officer of …
How Big Brother is helping to fight COVID-19
June 1, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, NHS, coronavirus, feeature, pharma, track and trace
Following the unprecedented disruption created by COVID-19, many governments are increasingly looking at using data from contact-tracing apps to help …
Russia to begin administering anti-viral COVID-19 drug next week
June 1, 2020Manufacturing and Production, Research and Development, Sales and Marketing COVID-19, Russia, coronavirus, pandemic, virus
Russia will start its roll out of the anti-viral drug Avifavir (favipiravir) to COVID-19 patients next week, according to the …
Gilead’s magrolimab shows promising responses in untreated myelodysplastic syndrome and acute myeloid leukaemia at ASCO 2020
June 1, 2020Research and Development, Sales and Marketing ASCO 2020, Cancer, Gilead, leukaemia, magrolimab
Gilead took the opportunity at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting to unveil new Phase 1b …
Significant lack of women and minorities involved in clinical trials for cardiometabolic medication, research shows
June 1, 2020Sales and Marketing cardio, cardiovascular, cvd
Women and minorities, particularly African Americans, continue to be under represented in clinical trials for cardiometabolic medication, according to a …
Lynparza secures CHMP recommendation in first-line BRCA-mutated metastatic pancreatic cancer
June 1, 2020Sales and Marketing AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza
Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has just secured recommendation for approval from the European Medicines …
US donates $1 billion to Oxford University’s COVID-19 vaccine in exchange for 300 million doses
June 1, 2020Sales and Marketing COVID-19, coronavirus
The US has given $1 billion to AstraZeneca to advance the development and production of the vaccine they are creating …
First ever benefit-risk analysis is “favourable” for remdesivir as COVID-19 treatment
May 29, 2020Medical Communications, Research and Development COVID-19, DSRU, Gilead, coronavirus, pharma, remdesivir
The UK-based Drug Safety Research Unit (DSRU) has reported its findings from the first ever systematic benefit-risk analysis of Gilead’s …
Leukaemia drug nilotinib shows promise against Alzheimer’s in small clinical study
May 29, 2020Medical Communications Alzheimer's, leukaemia
The leukemia drug nilotinib has shown promise in reducing the effects of Alzheimer’s disease and while having safe and minimal …
Top Ten most popular articles on Pharmafile.com this week
May 29, 2020Medical Communications COVID-19, coronavirus, top 10
GlaxoSmithKline features prominently in the news this week, as they pledged to pay a cash bonus of £1,500 to staff …
MSD and Eisai announce meaningful objective response rates for Keytruda+Lenvima combo in two cancer patient populations
May 29, 2020Medical Communications, Research and Development Lenvima, keytruda, pharma
MSD has pulled back the curtain on new data from two trials of its anti-PD-1 immunotherapy Keytruda (pemvbrolizmuab) in combination …
FDA advises recall of diabetes drug metformin over carcinogen concerns
May 29, 2020Medical Communications Carcinogens, MDMA
The FDA has asked that multiple pharmaceutical companies recall the formulations of their diabetes drug metformin after the regulatory body …
GlaxoSmithKline commits to the production of one billion doses of COVID-19 vaccine adjuvant in 2021
May 28, 2020Manufacturing and Production COVID-19, GSK, coronavirus, pharma, vaccines
GlaxoSmithKline has just come forward to commit to the manufacture and distribution of one billion doses of vaccine adjuvant against …
Novartis releases results of MS drug trials weeks ahead of FDA verdict
May 28, 2020Business Services MS, Novartis
Novartis has revealed clinical trial data from testing its anti-CD20 leukameia drug Arzerra (ofatumumab) in patients with multiple sclerosis (MS). …
BMS’ Zeposia becomes first S1P receptor modulator available in Europe for relapsing remitting multiple sclerosis
May 28, 2020Sales and Marketing Avonex, Bristol-Myers Squibb, EU, Europe, Zeposia, bristol myers squibb, multiple sclerosis
Bristol Myers Squibb is celebrating after its oral therapy Zeposia (ozanimod), secured European Commission for the treatment of relapsing remitting …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
